Global immuno-oncology drug development has dramatically expanded in the last ten years. Developers of these new therapies need more predictive platforms with improved clinical translation. Highly immunodeficient mice enable co-engraftment of human immune cells (peripheral blood mononuclear cells or hematopoietic stem cells) and human tumors that become immune infiltrated. These platforms enable the testing of therapies designed for human targets that capture human-specific biological responses. They also include genetic diversity to capture the human variation of response typically observed in clinical applications. These in vivo systems are also able to capture the systemic and holistic consequences of toxic cytokine release, enabling the evaluation of safety. Immune humanized platforms are ideal for lead optimization and safety data sets supporting Investigational New Drug (IND) applications.
Join us as we present preclinical data demonstrating:
- Monoclonal antibody-based human immune modulation
- Donor-specific differences in bispecific antibody-mediated tumor efficacy and cytokine release
- CAR T cell-mediated tumor efficacy and safety